Boris Rijavec

Dr. Boris Rijavec

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NRNikolina Rijavec
Nikolina Rijavec
BRBoris Rijavec
Boris Rijavec
Concurrent exposure to analgesic and psychotropic drugs is frequent in patients with pain, psychiatric comorbidity, frailty, or acute-care needs. The clinically important question is whether analgesics and psychotropic drugs act on the same metabolic, transporter, receptor, ion-channel, or cellular stress systems. This narrative mechanistic review discusses those points of contact. CYP-mediated inhibition or induction, phenoconversion, altered parent-to-metabolite ratios, and blood–brain barrier transporter effects can change both systemic and central exposure, particularly through CYP2D6, CYP3A4, CYP2C9, CYP2B6, and P-glycoprotein. Pharmacodynamic toxicity may involve serotonergic excess, opioid and GABAergic effects in respiratory-control networks, hERG/IKr-related loss of repolarization reserve, or dopamine D2 receptor blockade. Non-opioid analgesics and psychotropic background therapy add further pathways involving renal and gastrointestinal vulnerability, hematological toxicity, mitochondrial injury, and altered central nervous system function. At the cellular level, mitochondrial dysfunction, oxidative stress, calcium dysregulation, and endoplasmic reticulum stress are discussed primarily as mechanistic or preclinical contributors unless direct clinical evidence is available. Overall, analgesic–psychotropic co-exposure is presented as a clinically important example of pathway convergence, while pharmacogenomic and computational approaches are interpreted in relation to drug exposure, organ reserve, and patient-specific vulnerability.

Verified
Journal Article
Open access
PDF file
BRBoris Rijavec
Boris Rijavec
MSMensur Salihovic
Mensur Salihovic
TMTomislav Mirković
Tomislav Mirković
Local anesthetics are widely used across local and regional anesthesia, pain medicine, emergency care, and dentistry. Their therapeutic effect is based mainly on reversible voltage-gated sodium channel inhibition, but toxicity is not limited to this mechanism. This narrative review integrates molecular evidence on systemic and tissue-specific local anesthetic toxicity. Bupivacaine remains the prototypical cardiotoxic agent, reflecting the convergence of high lipophilicity, persistent cardiac ion channel effects, myocardial accumulation, impaired mitochondrial bioenergetics, altered fatty acid metabolism, calcium dyshomeostasis, and membrane-level injury. Across experimental and translational models, local anesthetics may also induce broad cytotoxicity in various cell types. These effects are primarily concentration- and exposure time-dependent and are modified by route, tissue perfusion, local clearance, metabolic reserve, developmental or physiological vulnerability, and repair capacity. Current experimental, translational, and stem cell-based models provide mechanistic insight but cannot be interpreted as direct clinical dose equivalents. Future studies should link drug type, concentration, formulation, route, exposure duration, patient vulnerability, and tissue-specific outcomes to improve route-specific safety assessment.